Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964089 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL390826 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL17871701 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL31388217 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL31128130 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| Hydrochloric Acid SCHEMBL17871800 | 0.98 | MC4R (0.53) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL5792053 | 0.98 | MC4R (0.55) | MC4RKEAP1CYP3A4GAAKCNQ2 | |
| Methylene Chloride SCHEMBL27881490 | 0.95 | MC4R (0.54) | MC4RKEAP1CYP3A4GAA | |
| SCHEMBL19665213 | 0.88 | KEAP1 (0.45) | MC4RKEAP1GAAMAPK1KCNQ2 | |
| Glutarate SCHEMBL2343643 | 0.87 | MC4R (0.53) | MC4RCYP3A4GAAKCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364977-A1 | Process for the enantiomeric enrichment of 3-methyl-1-(2-piperidinophenyl)-1-butylamine | Reuter Chemische Apparatebau KG (DE) | 2011-09-14 | — | — | EP | claimed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | claimed |
| US-7041830-B2 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-05-09 | — | — | US | claimed |
| US-20040192921-A1 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | claimed |
| EP-0965591-B1 | Process for the preparation of (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-04 | — | — | EP | claimed |
| EP-0965591-A1 | (s)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine, its salts, synthesis and use in the long term therapy of diabetes mellitus | Boehringer Ingelheim Pharma KG (DE) | 1999-12-22 | — | — | EP | claimed |
| EP-0207331-B1 | Solid forms of 2-ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-amino-carbonylmethyl]-benzoic acid, medicaments containing these forms and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-05-23 | — | — | EP | claimed |
| EP-0207331-A1 | Solid forms of 2-ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-amino-carbonylmethyl]-benzoic acid, medicaments containing these forms and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-01-07 | — | — | EP | claimed |
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| CN-119431272-A | Preparation method of (S) -3-methyl- (2-piperidylphenyl) -1-butylamine acetyl glutamate | 北京斯利安药业有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-3573961-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2023-10-25 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| CN-115141871-A | Preparation method of peramivir intermediate | 福建未来药业有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115141871-A | Preparation method of peramivir intermediate | 福建未来药业有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-0589874-B1 | USE OF (S)(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID FOR THE PREPARATION OF A LONGLASTING ANTIDIABETIC MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-09-08 | — | — | EP | disclosed |
| US-5312924-A | Compounds for lowering blood sugar and effecting metabolism | DR. KARL THOMAE GMBH (DE) | 1994-05-17 | — | — | US | disclosed |
| US-5216167-A | Hypoglycemic agents | DR. KARL THOMAE GMBH (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0207331-B1 | Solid forms of 2-ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-amino-carbonylmethyl]-benzoic acid, medicaments containing these forms and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0208200-B1 | PHENYLACETIC-ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1990-04-25 | — | — | EP | disclosed |
| EP-0208200-A1 | Phenylacetic-acid derivatives, pharmaceutical compositions containing them and processes for their production | Dr. Karl Thomae GmbH (DE) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192921-A1 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | GPR119, GLP1R, IRS1 | MC4R 274/4885KEAP1 1440/4885CYP3A4 72/4885 |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | MC4R 1094/4885KEAP1 4787/4885CYP3A4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.